Another twist in the Biosecure drama leaves bill’s fate uncertain

Despite a setback from the Senate Armed Services Committee, which declined to add the Biosecure Act to the bipartisan consensus draft of a must-pass defense bill, the legislation could still reach President Joe Biden’s desk this year.

Shares of contract development, research and manufacturing companies that would be directly affected by proposed restrictions on U.S. government contracting with Chinese biotech companies jumped Friday on the news that the Biosecure Act wasn’t included in a package of 93 amendments to the FY25 National Defense Authorization Act (NDAA). ...